Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumab.
Bhisitkul RB, Campochiaro PA, Blotner S, Quezada-Ruiz C, Liu M, Haskova Z. Bhisitkul RB, et al. Among authors: blotner s. Br J Ophthalmol. 2024 Aug 22;108(9):1216-1225. doi: 10.1136/bjo-2022-323120. Br J Ophthalmol. 2024. PMID: 38290802 Free PMC article. Clinical Trial.
Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis.
Sadda S, Holekamp NM, Sarraf D, Ebraheem A, Fan W, Hill L, Blotner S, Spicer G, Gune S. Sadda S, et al. Among authors: blotner s. Graefes Arch Clin Exp Ophthalmol. 2022 Dec;260(12):3781-3789. doi: 10.1007/s00417-022-05716-4. Epub 2022 Jun 10. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35687173 Free PMC article. Clinical Trial.
Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
Freund KB, Staurenghi G, Jung JJ, Zweifel SA, Cozzi M, Hill L, Blotner S, Tsuboi M, Gune S. Freund KB, et al. Among authors: blotner s. Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2437-2447. doi: 10.1007/s00417-022-05586-w. Epub 2022 Mar 3. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35239009 Free PMC article. Clinical Trial.
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A, Miller WH Jr, Blay JY, Gietema JA, Bang YJ, Mileshkin LR, Hirte HW, Higgins B, Blotner S, Nichols GL, Chen LC, Petry C, Yang QJ, Schmitt C, Jamois C, Siu LL. Italiano A, et al. Among authors: blotner s. Invest New Drugs. 2021 Dec;39(6):1587-1597. doi: 10.1007/s10637-021-01141-2. Epub 2021 Jun 28. Invest New Drugs. 2021. PMID: 34180037 Free PMC article. Clinical Trial.
35 results